Search

This outcome is in accordance with that of a Japanese phase III multicentre study of 12 GPP patients treated with SEK during 52 weeks.1 Ten of their patients (88.33%) achieved a significant improvement, and this response was sustained until the end of the follow-up period. Successful therapy with secukinumab in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation. Two patients had a secondary failure and discontinued the therapy at 12 and 18 months because of lack of effectiveness. [Extracted from the article]

Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real‐life clinical practice. Ninety patients with plaque psoriasis recruited from—Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR <0.15 were included in a multiple regression model. Sixty three percent of patients achieved an absolute PASI ≤1 at 6 months, while 71% did so after 12 months. Disease duration (>27 years) and weight (>76 kg) were associated with treatment response; after correcting by these factors, no association (FDR >0.15) was found for any polymorphism and response to tildrakizumab at 6 months. The analysis at 12 months identified the genotype GG for rs610604 (TNFAIP3), CT for rs9373839 (ATG5), and delCTGT/delCTGT for rs72167053 (PDE4D) as risk factors to not achieve an optimal response (PASI ≤1), while CT for rs708567 (IL17RC) was protective, independently of weight and disease duration (FDR <0.15). The final multivariable model at 12 months showed an AUC of 0.90 (95% CI 0.82 to −0.98). We identified a set of polymorphisms that could be helpful to identify psoriatic patients with an optimal response to tildrakizumab at 12 months in real‐world practice conditions. [ABSTRACT FROM AUTHOR]

This article discusses the effectiveness of secukinumab (SEC) for the treatment of erythrodermic psoriasis (EP), a rare and severe form of psoriasis. The study was conducted in daily practice conditions and included 16 patients from Portuguese and Spanish hospitals. The results showed that SEC was effective and safe for treating EP, with a significant improvement observed at 3 months and sustained effectiveness over a longer follow-up period. This study represents the largest series of EP patients treated with SEC and provides evidence for SEC as a potential treatment alternative for this severe clinical form of psoriasis. [Extracted from the article]

Summary: Background: The cutaneous manifestations of COVID‐19 disease are poorly characterized. Objectives: To describe the cutaneous manifestations of COVID‐19 disease and to relate them to other clinical findings. Methods: We carried out a nationwide case collection survey of images and clinical data. Using a consensus we described five clinical patterns. We later described the association of these patterns with patient demographics, the timing in relation to symptoms of the disease, the severity and the prognosis. Results: The lesions may be classified as acral areas of erythema with vesicles or pustules (pseudo‐chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%) and livedo or necrosis (6%). Vesicular eruptions appear early in the course of the disease (15% before other symptoms). The pseudo‐chilblain pattern frequently appears late in the evolution of the COVID‐19 disease (59% after other symptoms), while the rest tend to appear with other symptoms of COVID‐19. The severity of COVID‐19 shows a gradient from less severe disease in acral lesions to more severe in the latter groups. The results are similar for confirmed and suspected cases, in terms of both clinical and epidemiological findings. Alternative diagnoses are discussed but seem unlikely for the most specific patterns (pseudo‐chilblain and vesicular). Conclusions: We provide a description of the cutaneous manifestations associated with COVID‐19 infection. These may help clinicians approach patients with the disease and recognize cases presenting with few symptoms. What is already known about this topic? Previous descriptions of cutaneous manifestations of COVID‐19 were case reports and mostly lacked illustrations. What does this study add? We describe a large, representative sample of patients with unexplained skin manifestations and a diagnosis of COVID‐19, using a consensus method to define morphological patterns associated with COVID‐19.We describe five clinical patterns associated with different patient demographics, timing and prognosis, and provide illustrations of these patterns to allow for easy recognition. Linked Editorial: Hay et al. Br J Dermatol 2020; 183:3–4. Plain language summary available online [ABSTRACT FROM AUTHOR]

Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population Dear Editor, Previous studies based on insurance claim databases have described a slightly decreased pregnancy rate in women with psoriasis. We found that the fertility age-standardized rate among women of childbearing age with moderate-to-severe psoriasis was less than half the fertility rate for women of the same age in the Spanish population. [Extracted from the article]

The article discusses a study on the association between 192 single-nucleotide polymorphisms and moderate-to-severe chronic plaque psoriasis. It tackles the recruitment of research participants, the method used in the study, and calculation of the Hardy-Weinberg equilibrium, allele and genotype frequencies.